HempNewsBreaks – PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Developmental Pipeline Houses Comprehensive Range of Advanced Therapeutic Products

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) holds a wide array of advanced therapeutic products in its development pipeline, including its Sol-gel delivery platform. The Sol-gel nose-to-brain drug delivery platform delivers a therapeutic compound to a targeted site at a deliberate, controlled rate. A recent article further discussing the company reads: “The Sol-gel platform allows a therapeutic agent to be administered via the nostrils, where it changes rapidly to a gel upon contact with mucosal tissue. The gel, which continues to line the nasal passage for up to seven days, slowly releases the therapeutic agent over time. It was developed in conjunction with the University of Queensland in Australia. PreveCeutical’s team in Australia recently began testing alternative spray devices for use with the Sol-gel system, and a non-disclosure agreement has been signed with one company which has a successful drug approval track record and good manufacturing standards for pharmaceutical devices.”

To view the full article, visit http://cnw.fm/9LXeD

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information, visit the company’s website at www.PreveCeutical.com

More from CannabisNewsBreaks

• HempNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Restructures $7 Million in Legacy Debt, Secures Repurchase Option
• HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model
• HempNewsBreaks – CannabisNewsWire Named Official Newswire of 2025 Cannabis Means Business Expo in NYC 

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net